Befloxatone (Synthelabo)

Area of Science:

• Pharmacology
• Neuroscience
• Psychiatry

Background:

• Synthelabo is developing befloxatone, a novel long-acting, selective, and reversible monoamine oxidase A (MAO-A) inhibitor.
• Befloxatone is intended for the treatment of depression, social phobias, and panic disorders.

Purpose of the Study:

• To evaluate the safety and efficacy of befloxatone in treating depression, social phobias, and panic disorders.
• To assess the cognitive and psychomotor effects of befloxatone in healthy elderly volunteers.

Main Methods:

• Phase III trials for depression have commenced in France.
• Phase II trials in Europe and the US investigated befloxatone for depression, social phobias, and panic disorders.
• A dose-ranging study confirmed safety in patients with major depressive disorders. Phase I trials assessed cognitive and psychomotor function in elderly volunteers using objective and subjective tests.

Main Results:

• Befloxatone demonstrated a good safety profile with negligible tyramine effect, lacking sedative, convulsant, anticholinergic, and cardiovascular effects.
• A 10 mg oral dose in elderly volunteers showed no detrimental effects on skilled performance, memory, or sleep patterns, with a notable improvement in long-term memory.
• [11C]-befloxatone proved to be an effective ligand for positron emission tomography studies of MAO-A.

Conclusions:

• Befloxatone is a potentially safe and effective treatment for depression, social phobias, and panic disorders.
• The drug's pharmacokinetic profile suggests suitability for once-daily oral administration.
• Befloxatone may offer cognitive benefits, particularly in memory, without negatively impacting skilled performance or sleep.